Search

Chase Morgan (University of California San Diego), Haley Atkins (Loyola University Chicago) and colleagues published a new review on phage therapy for urinary tract infections, showing phage therapy for this indication is promising, but nee

PHIOGEN is seeking to explore patient experiences with recurrent UTIs and attitudes toward phage therapeutics: the study involves a brief screening questionnaire followed by a survey for qualified participants who experience ongoing UTI sym

Paul Kim (Locus Biosciences, Inc.) and colleagues published a paper on the results of the first phase of their Phase 2 ELIMINATE clinical trial, where they used a CRISPR-Cas3-enhanced phage cocktail to treat uncomplicated urinary tract infe

Tram Le and colleagues show the therapeutic potential of IV phage for recurrent urinary tract infections, describing a kidney transplant recipient with ESBL Klebsiella pneumoniae who was successfully treated with 4 weeks of IV phage therapy

Video series: 3-part interview on phage therapy for recurrent UTI and beyond: Dr. Sabrina Green, Dr. Saima Aslam and Dr. Austen Terwilliger.

PhD project to explore the molecular biology of UTI phage cocktails

Adaptive Phage Therapeutics dosed the first patient in their phase 1/2 study to evaluate their PhageBank™ technology as a treatment for UTIs.

As there is currently no gold standard for developing a phage cocktail, Melissa Haines (University of Leicester, UK) and colleagues set out to describe a novel approach to phage cocktail development by comparing different methods side by si

Pherecydes Pharma is joining forces with BIOASTER, a French not-for-profit foundation that brings together academic, industry and its own capacities to execute high-impact, collaborative projects, to explore the use of phage therapy to trea

Pherecydes Pharma is joining forces with BIOASTER, a French not-for-profit foundation that brings together academic, industry and its own capacities to execute high-impact, collaborative projects, to explore the use of phage therapy to trea

This NPR article discusses Locus Biosciences' upcoming E. coli urinary tract infection phage therapy trial and interviews one of the trial volunteers—Alfonso Evans, a US Army veteran who was paralyzed by a spinal cord injury and thus suffer

This NPR article discusses Locus Biosciences' upcoming E. coli urinary tract infection phage therapy trial and interviews one of the trial volunteers—Alfonso Evans, a US Army veteran who was paralyzed by a spinal cord injury and thus suffer

Dr. Barbara Trautner, Dr. Anthony Maresso and Dr. Frank Ramig We have an exciting new postdoc training and research opportunity recently made possible via the acquisition of a VA Merit Award to discover and develop therapeutic phages to tre

Dr. Barbara Trautner, Dr. Anthony Maresso and Dr. Frank Ramig We have an exciting new postdoc training and research opportunity recently made possible via the acquisition of a VA Merit Award to discover and develop therapeutic phages to tre

Completed. Checked 2026-10-03. Study LBx-1001 is a multi-center randomized, double-blind study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of LBP-EC01 in patients with indwelling urinary catheters, or